Dr. Ruchi Shah is a seasoned professional with more than 10 years of experience in the field of nucleic acid delivery, gene editing, vaccines, vaccine adjuvant development, and biologics.
Ruchi started her career as Scientist at GSK Vaccines in 2015, focusing on mRNA -based liposomal vaccines. In the following year, she continued her path at Intellia Therapeutics in delivering CRISPR Cas9-based therapeutics with lipid nanoparticles and advanced fast to a Senior Scientist in non-viral delivery and delivery science. She also worked at Moderna Therapeutics to enable high throughput screening in their platform group.
Ruchi’s career progressed rapidly at Eli Lilly and Company where she started as Associate Director in 2020, leading internal and external projects to develop lipid nanoparticle formulations for early-phase medical treatments. In October 2022, she was promoted to Director of Genetic Medicine, continuing her work in developing advanced therapeutic platforms for the medical industry.
In April 2023, Ruchi joined EMD Millipore Corporation within the Targeted mRNA Delivery team as the LNP Formulation Director, heading a lab team that is capable of both lipid design innovation and high throughput experimentation, advancing research and development in this rapidly expanding field.